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Familial Risk of Sj€ogren’s Syndrome and Co-aggregation
of Autoimmune Diseases in Affected Families
A Nationwide Population Study
Chang-Fu Kuo,1 Matthew J. Grainge,2 Ana M. Valdes,2 Lai-Chu See,3 Shue-Fen Luo,4
Kuang-Hui Yu,4 Weiya Zhang,2 and Michael Doherty2
Objective. To investigate familial aggregation of
Sj€ogren’s syndrome (SS) and the relative risks (RRs) of
other autoimmune disease in relatives of patients with SS.
Methods. We identified 23,658,577 beneficiaries
enrolled in the Taiwan National Health Insurance sys-
tem in 2010, of whom 12,754 had SS. We identified
21,009,551 parent–child relationships and 17,168,340
pairs of full siblings. The familial risks of SS and other
autoimmune diseases, tetrachoric correlation, and fami-
lial transmission were estimated.
Results. We identified 105 patients with SS who had
an affected first-degree relative. The RR of SS was 18.99
(95% confidence interval [95% CI] 9.76–36.93) in siblings
of patients with SS, 11.31 (95% CI 8.34–15.33) in offspring,
and 12.46 (95% CI 9.34–16.62) in parents. Tetrachoric cor-
relation coefficients were 0.53 (95% CI 0.41–0.65) for
cotwins of affected individuals and 0.21 (95% CI 0.16–0.26)
for full siblings. The familial transmission (heritability
plus shared environmental contribution) was 0.54 (95% CI
0.44–0.77). In first-degree relatives of patients with SS, the
RRs were 2.95 (95% CI 2.33–3.73) for rheumatoid arthritis,
6.25 (95% CI 5.15–7.58) for systemic lupus erythematosus,
2.39 (95% CI 0.77–7.41) for systemic sclerosis, 0.71 (95% CI
0.10–5.07) for idiopathic inflammatory myopathy, 1.97
(95% CI 1.29–3.02) for type 1 diabetes mellitus, 3.38 (95%
CI 1.26–9.05) for multiple sclerosis, 1.67 (95% CI 0.83–
3.33) for myasthenia gravis, 1.25 (95% CI 1.04–1.50) for
psoriasis, 1.21 (95% CI 0.39–3.76) for inflammatory bowel
disease, and 2.29 (95% CI 1.19–4.40) for vasculitis.
Conclusion. The risk of SS and other autoim-
mune diseases is increased in relatives of patients with
SS, and more than one-half of phenotypic variance in
SS can be explained by familial factors.
Sj€ogren’s syndrome (SS) is an autoimmune disease
characterized by dry eyes and dry mouth and pathologic
features such as lymphocytic infiltration and destruction
of the lacrimal and salivary glands (1). In addition to exo-
crinopathy, SS may involve many organ systems and can
cause heterogeneous clinical presentations, including
arthritis (2) and renal disease (3). The prevalence of SS
varies widely depending on the study design and the popu-
lation studied. A recent report summarizing 3 population-
based studies in Greece, Norway, and France estimated
the prevalence of SS in Europe to be 0.04% (4). Using the
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which contains health information for almost all inhabi-
tants of Taiwan, our group recently estimated that the
prevalence of SS in Taiwan was 0.06% in 2005 (5).
Familial clustering of SS (6–14) as well as its co-
aggregation with other autoimmune diseases (15,16) have
been suggested, but solid evidence for both notions is
sparse. Several case reports have described concordance
of SS in twins (6–9) and in families with $2 cases of SS
(10–14). The tendency of SS to cluster within families sug-
gests a role for familial factors such as genes and shared
environment in the pathogenesis of the disease. Conse-
quently, efforts to define the pathogenesis of SS have
focused on genetic factors, and recent studies successfully
identified susceptibility loci for SS (17–21). Environmental
factors (such as viruses) and hormonal factors are
also thought to participate in disease pathogenesis (22).
Although these reports support the contribution of both
genetic and shared environmental factors in the suscepti-
bility to SS, they provide no quantitative estimates of the
measures of familial risks of SS and the proportion of phe-
notypic variance that can be explained by familial factors
(familial transmission). In addition, estimates of the
respective risks of other autoimmune diseases in relatives
of patients with SS have not been reported previously.
Therefore, using genealogy and linked health
information derived from the NHIRD, we conducted this
nationwide study comprising essentially the entire popula-
tion of Taiwan in 2010 to determine familial aggregation
of SS and to assess the relative contribution of familial fac-
tors to susceptibility to the disease. In addition, we also
estimated the relative risks (RRs) of other autoimmune
diseases associated with a family history of SS.
PATIENTS AND METHODS
Study population. This study was approved by the
Institutional Review Board of Chang Gung Memorial Hospital
(approval no. 101-2178B) and by the National Health Research
Institutes, which compiles data for the NHIRD. We constructed
a cohort containing all beneficiaries enrolled in the Taiwan
National Health Insurance (NHI) system in 2010, using data
from the registry for beneficiaries, the registry for patients with
catastrophic illness, and data sets of ambulatory care expendi-
tures and details of ambulatory case orders, all of which are com-
ponents of the NHIRD. Enrollment in the NHI system is
mandatory by law in Taiwan. In 2010, .99.5% of the general
population in Taiwan was covered by the insurance (23). The
NHIRD contains registration information and data for original
claims for reimbursement, including comprehensive information
on personal details, socioeconomic status, family relationships,
dates of clinical visits, medical diagnoses, medical expenditures,
prescription details, examinations, and procedures. Data are
updated biannually. All data for a given individual are linked by
a unique national identification number that is associated with
every record for that individual in the database. To ensure con-
fidentiality, identification numbers were encrypted before being
released for research, but the uniqueness of the encrypted identi-
fication is retained to ensure valid internal linkage.
Methods of identifying first-degree relatives and family
ascertainment have been previously reported (see Supplemen-
tary material, available on the Arthritis & Rheumatology web site
at http://onlinelibrary.wiley.com/doi/10.1002/art.39127/abstract)
(24). Briefly, lineal blood relatives and spouses can be directly
identified using the indicators of relationships and unique
national identification numbers. Full siblings of an individual
are identified if they shared the same parents. Twins are full sib-
lings with the same date of birth (61 day), but twin zygosity
cannot be derived from the database. To consider the correla-
tion among individuals from the same family, we grouped indi-
viduals into families according to their relationships. In total,
21,009,551 parent–child relationships, 17,168,340 pairs of full
siblings, and 342,066 twin pairs were identified, and these rela-
tionships were used to assemble 4,229,301 families, with a mean
family size of 4.8 persons, spanning up to 5 generations.
Case definition of SS and other autoimmune diseases.
The case definition for SS was a person with a catastrophic ill-
ness certificate for SS (International Classification of Diseases,
Ninth Revision code 7102). The holders of a catastrophic ill-
ness certificate are entitled to a waiver of medical copayments.
In order for a patient to receive a certificate for SS, the diag-
nosis must be supported by comprehensive clinical and labora-
tory assessments, and this information is required by the
insurance administration for a review by commissioned expert
panels to confirm the diagnosis before approval of waivers.
The panel reviews the diagnosis, in compliance with the
updated classification criteria. For instance, the preliminary
European classification criteria for SS (25) and classification
criteria by the American–European Consensus Group (26)
were used in recent years to assist the review of certificate
applications for SS. To eliminate patients with secondary SS,
only those without a catastrophic illness certificate for rheuma-
toid arthritis (RA), systemic lupus erythematosus (SLE), sys-
temic sclerosis, or idiopathic inflammatory myopathy were
included. We also identified patients with other autoimmune
diseases including RA, SLE, systemic sclerosis, idiopathic
inflammatory myopathy, type 1 diabetes mellitus, multiple
sclerosis, myasthenia gravis, psoriasis, inflammatory bowel dis-
ease, and vasculitis (for full code lists, see Supplementary
material, available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.39127/abstract).
Covariates. We considered age, sex, socioeconomic
factors (place of residence, occupation, and income level), and
family size as factors that might confound or modify the fami-
lial associations. A place of residence for each individual was
categorized according to the level of urbanization (27). Occu-
pations were classified into 5 categories, and income levels
were categorized into sex-specific income quintiles (for addi-
tional details, see Supplementary material, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.39127/abstract).
Statistical analysis. The prevalence of SS among indi-
viduals with affected first-degree relatives and the general popula-
tion was calculated. Any individual with valid insurance
registration in 2010 who met the case definition of SS between
January 1, 1996 andDecember 31, 2010 was defined as a prevalent
case. The number of individuals in the general population in Tai-
wan was used as the denominator for the prevalence of SS in 2010.
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The recurrence risk for SS was defined as the likelihood of a diag-
nosis of SS in an individual with an affected first-degree relative
with a diagnosis of SS.We calculated the recurrence risk for a spe-
cific type of relative (parents, offspring, sibling, and twins) of
patients with SS as the prevalence of SS in individuals with a spe-
cific type of affected relative (28). The adjusted prevalence ratio
was used as a measure for the RR of SS (29) and was calculated as
the prevalence of SS among individuals with affected relatives
divided by the prevalence of SS in the general population. The
RR estimated in this study is equivalent to the relative recurrence
ratio, but for simplicity we refer to it as RR throughout. The mar-
ginal Cox proportional hazards model with an equal followup time
for all subjects (30), adjusted for age, sex, socioeconomic factors,
and family size, was used to estimate the RRs and 95% confidence
intervals (95% CIs). We used the robust sandwich estimator to
calculate corrected 95% CIs to account for possible case clustering
within families (31). This approach has been applied previously in
other diseases and validated (32). We also estimated tetrachoric
correlation coefficients to measure the degree of similarity in dif-
ferent types of relatives. We assumed that a continuous normally
distributed liability underlies the diagnosis of SS.
Heritability was defined as the proportion of phenotypic
variance that is attributable to genetic factors, and familial trans-
mission was defined as the sum of heritability and the proportion
attributable to shared environmental factors. Each of these val-
ues can be calculated using a polygenic liability model (33–35).
The familial transmission in this study was estimated as the func-
tion of the difference of normal deviation of the threshold from
the mean liability between individuals with affected siblings and
the normal population (for details, see Supplementary material,
available on the Arthritis & Rheumatology web site at http://onli-
nelibrary.wiley.com/doi/10.1002/art.39127/abstract).
The original model assumes zero common environmen-
tal variance, and therefore familial transmission equals herit-
ability. We consider this assumption not to be applicable in the
case of SS, however, considering known environmental factors
that may predispose to the disease and be shared among family
members (22). In a previous study by our group, we further
used spouses as a control to separate shared environmental
component and heritability (24). However, because SS predomi-
nantly affects females and its prevalence is low, it was not possi-
ble to identify enough affected spouse pairs to produce reliable
estimates. Therefore, we reported only familial transmission.
Next, for patients with SS, we calculated the probability of not
having a family history of SS (sporadic cases) according to the
formula based on the polygenic liability model developed by
Yang et al (36). We restricted family history to first-degree rela-
tives and assumed an average of 2 siblings in a family.
We further estimated the extent of familial co-
aggregation of other autoimmune diseases in affected families.
RRs and 95% CIs for RA, SLE, systemic sclerosis, idiopathic
inflammatory myopathy, type 1 diabetes mellitus, multiple scle-
rosis, myasthenia gravis, inflammatory bowel diseases, psoriasis,
and vasculitis were estimated as the adjusted prevalence ratio of
specified autoimmune diseases between individuals with a first-
degree relative with SS and the general population. We esti-
mated the RR for other autoimmune diseases using a marginal
Cox proportional hazards regression model with an equal fol-
lowup time for all subjects. The RRs were adjusted for age, sex,
and family size, and were considered case clustering within fam-
ilies by using the robust sandwich estimate. Two-tailed P values
less than or equal to 0.05 were considered significant. All analy-
ses were performed using SAS version 9.3.
RESULTS
Prevalence of SS in individuals with an affected
first-degree family member versus the general popula-
tion. The study population comprised 23,658,577 individ-
uals enrolled in the NHI system in Taiwan in 2010. There
Figure 1. Age-specific prevalence of Sj€ogren’s syndrome in individuals with a first-degree relative with Sj€ogren’s syndrome (broken line) and in
the general population (solid line) in Taiwan in 2010. Bars show 95% confidence intervals.
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were 12,754 individuals (11,462 women and 1,292 men)
with SS in the general population of Taiwan in 2010, which
is equivalent to a prevalence of 0.05% (0.10% in women
and 0.01% in men). In the general population of Taiwan
in 2010, 21,985 individuals (0.09%) had at least one first-
degree relative with SS. Among these individuals, 105 had
SS (prevalence 0.48%). The mean6 SD age of the
patients with SS was lower in those with a family history
(46.66 16.2 years) than in those without a family history
(57.06 14.2 years; P, 0.001, by Student’s t-test). For indi-
viduals with an affected first-degree relative, the age-
specific prevalence of SS was significantly higher than that
in the general population (Figure 1). Other characteristics
of the study population are shown in Table 1.
Relative risks of SS in individuals with affected
first-degree relatives. Table 2 shows the prevalence
(recurrence risk) of SS in individuals with an affected
first-degree relative, according to different relationships
and sexes of the affected individuals and their families.
Overall, having an affected first-degree relative with SS was
associated with an adjusted RR of 12.37 (95% CI
9.54–16.05) for the disease. Individuals with female and
male affected relatives had respective RRs for SS of 13.24
(95% CI 10.15–17.27) and 10.06 (95% CI 4.91–20.61), sug-
gesting that the sex of the affected relative did not influence
theRR.
In SS, the degree of genetic distance between family
relatives is associated with the RRs. The RRs of SS were
661.75 (95% CI 278.09–1,574.70) in cotwins of patients
with SS, 18.99 (95%CI 9.76–36.93) in siblings, 11.31 (95%
CI 8.34–15.33) in offspring, and 12.46 (95% CI 9.34–
16.62) in parents. In addition, the RRs increased with the
number of types of affected first-degree relatives. Com-
pared with the general population, individuals with 1 type
of affected first-degree relative had an RR of 12.71 (95%
CI 9.80–16.49), and those with 2 or more affected first-
degree relatives had an RR of SS of 70.36 (95% CI 10.28–
481.60).
Familial transmission and tetrachoric correla-
tion of SS. Overall, the tetrachoric correlation coeffi-
cient for first-degree relatives was 0.22 (95% CI 0.19–
0.24) (Table 2). The tetrachoric correlation coefficients
were estimated to be 0.53 (95% CI 0.41–0.65) for twins
and 0.21 (95% CI 0.16–0.26) for full siblings. Using a
polygenic liability model, we estimated that the familial
transmission for SS was 0.54 (95% CI 0.44–0.77). Given
the parameters estimated previously, 84.0% of SS patients
were expected to be sporadic cases.
Table 1. Baseline characteristics of the individuals with relatives affected by SS and the general population*
Variable
Women Men
At least 1
affected relative General population
P
At least 1
affected relative General population
P(n5 10,416) (n5 11,926,513) (n5 11,569) (n5 11,732,064)
Age, mean6 SD years 33.26 16.9 37.96 20.4 ,0.001 33.46 16.3 37.16 20.6 ,0.001
Patients with SS 95 (0.91) 11,462 (0.10) ,0.001 10 (0.09) 1,292 (0.01) ,0.001
Place of residence ,0.001 ,0.001
Urban 6,901 (66.25) 7,197,968 (60.35) 7,166 (61.94) 6,737,087 (57.42)
Suburban 2,664 (25.58) 3,209,020 (26.91) 3,051 (26.37) 3,372,637 (28.75)
Rural 707 (6.79) 1,087,991 (9.12) 793 (6.85) 1,098,656 (9.36)
Unknown 144 (1.38) 431,534 (3.62) 559 (4.83) 523,684 (4.46)
Income level ,0.001 ,0.001
Quintile 1 1,499 (14.39) 1,960,003 (16.43) 1,690 (14.61) 2,117,136 (18.05)
Quintile 2 1,549 (14.87) 1,839,576 (15.42) 1,389 (12.01) 1,495,341 (12.75)
Quintile 3 2,138 (20.53) 3,161,293 (26.51) 2,398 (20.73) 3,135,633 (26.73)
Quintile 4 2,196 (21.08) 2,252,173 (18.88) 2,534 (29.86) 2,294,886 (19.56)
Quintile 5 2,875 (27.60) 2,274,656 (19.07) 2,986 (25.81) 2,163,222 (18.44)
Unknown 159 (1.53) 438,812 (3.68) 572 (4.94) 525,846 (4.48)
Occupation ,0.001 ,0.001
Dependent of insured
individual
3,835 (36.82) 4,924,319 (41.29) 3,952 (34.16) 4,285,015 (36.52)
Civil servant, teacher,
military personnel,
and veterans
706 (6.78) 401,734 (3.37) 660 (5.70) 582,717 (4.97)
Non–manual labor
worker and
professional
3,469 (33.30) 3,031,660 (25.42) 4,323 (37.37) 3,325,548 (28.35)
Manual labor worker 1,534 (14.73) 2,612,534 (21.91) 1,498 (12.95) 2,272,550 (19.37)
Other 872 (8.37) 956,266 (8.02) 1,136 (9.82) 12,66234 (10.79)
* Except where indicated otherwise, values are the number (%). SS5 Sj€ogren’s syndrome.
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Table 2. Relative risks (RRs) and tetrachoric correlation for Sj€ogren’s syndrome in different kinships*
Type of affected
relative, sex of
affected relative, sex
of individual No. of cases Prevalence, % RR (95% CI)†
Tetrachoric correlation
coefficient (95% CI)
Any relative
Female
Female 88 0.94 13.75 (10.36–18.26) 0.24 (0.21–0.26)
Male 8 0.08 10.37 (5.21–20.62) 0.17 (0.10–0.24)
All 96 0.48 13.24 (10.15–17.27) 0.22 (0.19–0.24)
Male
Female 7 0.67 8.92 (4.28–18.61) 0.17 (0.09–0.24)
Male 2 0.17 21.15 (2.97–150.36) 0.21 (0.08–0.33)
All 9 0.41 10.06 (4.91–20.61) 0.17 (0.10–0.23)
All
Female 95 0.91 13.24 (10.13–17.31) 0.24 (0.21–0.26)
Male 10 0.09 11.57 (5.90–22.67) 0.18 (0.12–0.24)
All 105 0.48 12.37 (9.54–16.05) 0.22 (0.19–0.24)
Parent
Female, mother
Female 39 0.55 13.12 (9.55–18.02) 0.17 (0.13–0.20)
Male 5 0.06 14.26 (5.97–34.07) 0.14 (0.06–0.22)
All 44 0.29 13.04 (9.68–17.57) 0.15 (0.12–0.18)
Male, father
Female 3 0.38 8.47 (2.72–26.36) 0.11 (0.01–0.21)
Male 0 0 NA NA
All 3 0.17 7.37 (2.37–22.92) 0.09 (0.01–0.18)
All
Female 42 0.53 12.65 (9. 32–17.17) 0.17 (0.13–0.20)
Male 5 0.05 12.71 (5.32–30.36) 0.13 (0.05–0.21)
All 47 0.28 12.46 (9.34–16.62) 0.15 (0.12–0.18)
Offspring
Female, daughter
Female 33 2.65 11.79 (8.43–16.50) 0.32 (0.28–0.36)
Male 3 0.29 8.94 (2.90–27.54) 0.26 (0.15–0.37)
All 36 1.59 11.41 (8.28–15.74) 0.31 (0.27–0.34)
Male, son
Female 4 2.74 11.79 (4.49–30.99) 0.28 (0.18–0.39)
Male 0 0 NA NA
All 4 1.58 10.44 (3.98–27.41) 0.27 (0.17–0.36)
All
Female 37 2.66 11.79 (8.59–16.19) 0.33 (0.29–0.37)
Male 3 0.27 8.04 (2.61–24.78) 0.25 (0.14–0.36)
All 40 0.31 11.31 (8.34–15.33) 0.25 (0.14–0.36)
Sibling
Female, sister
Female 14 1.36 21.78 (10.77–44.12) 0.24 (0.18–0.30)
Male 0 0 NA NA
All 14 0.63 18.92 (9.37–38.40) 0.21 (0.16–0.26)
Male, brother
Female 0 0 NA NA
Male 2 1.77 153.48 (20.90–1,127.20) 0.39 (0.25–0.53)
All 2 0.93 19.72 (2.89–1,34.54) 0.21 (0.09–0.34)
All
Female 14 1.23 19.09 (9.42–38.68) 0.23 (0.17–0.29)
Male 2 0.15 20.13 (2.81–144.30) 0.20 (0.08–0.32)
All 16 0.65 18.99 (9.76–36.93) 0.21 (0.16–0.26)
Twin
Female, twin sister
Female 4 36.36 756.32 (332.32–1,721.27) 0.57 (0.43–0.70)
Male 0 0 NA NA
All 4 28.57 723.05 (314.11–1,664.39) 0.55 (0.43–0.68)
Male, twin brother
Female 0 0 NA NA
Male 0 0 NA NA
All 0 0 NA NA
All
Female 4 33.33 695.68 (296.16–1,634.17) 0.55 (0.42–0.69)
Male 0 0 NA NA
All 4 23.53 661.75 (278.09–1,574.70) 0.53 (0.41–0.65)
* 95% CI5 95% confidence interval; NA5 not applicable.
† Adjusted for age, sex, place of residence, quintile of income level, occupation, and family size.
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Co-aggregation of other autoimmune diseases.
Table 3 shows the adjusted RRs (95% CIs) for other auto-
immune diseases in individuals with affected first-degree
relatives compared with the general population. The RR
in individuals with a first-degree relative with SS was 2.95
(95% CI 2.33–3.73) for RA, 6.25 (95% CI 5.15–7.58) for
SLE, 2.39 (95% CI 0.77–7.41) for systemic sclerosis, 0.71
(95% CI 0.10–5.07) for idiopathic inflammatory myopathy,
1.97 (95% CI 1.29–3.02) for type 1 diabetes mellitus, 3.38
(95% CI 1.26–9.05) for multiple sclerosis, 1.67 (95% CI
0.83–3.33) for myasthenia gravis, 1.25 (95% CI 1.04–1.50)
for psoriasis, 1.21 (95% CI 0.39–3.76) for inflammatory
bowel disease, and 2.29 (95% CI 1.19–4.40) for vasculitis.
DISCUSSION
This study is the first to investigate the risk of
SS in individuals with affected first-degree relatives
and to estimate the familial transmission of SS in a
general population. We observed that the prevalence
of SS in relatives of patients with the disease is 12-
fold higher than that in the general population, and
that genetic distance is associated with the magnitude
of risk. The familial transmission of SS was 0.54.
Despite this, most cases of SS are expected to be spo-
radic, based on the polygenic liability model. Further-
more, the prevalence of other autoimmune diseases is
Table 3. Relative risks (RRs) of other autoimmune diseases in individuals with first-degree relatives with Sj€ogren’s
syndrome*
With affected relatives General population
RR (95% CI)†
No. of
cases Prevalence, %
No. of
cases Prevalence, %
Rheumatoid arthritis
Female 50 0.48 29,527 0.25 2.87 (2.18–3.78)
Male 18 0.16 7,887 0.07 3.21 (2.02–5.09)
All 68 0.31 37,414 0.16 2.95 (2.33–3.73)
Systemic lupus erythematosus
Female 96 0.92 16,822 0.14 6.24 (5.10–7.65)
Male 13 0.11 1,984 0.02 6.31 (3.65–10.88)
All 109 0.50 18,806 0.08 6.25 (5.15–7.58)
Systemic sclerosis
Female 2 0.02 1,493 0.01 2.12 (0.53–8.50)
Male 1 0.01 395 0.003 3.24 (0.46–22.91)
All 3 0.01 1,888 0.01 2.39 (0.77–7.41)
Idiopathic inflammatory myopathy
Female 1 0.01 1,259 0.01 1.10 (0.16–7.86)
Male 0 0 548 0.005 NA
All 1 0.005 1,807 0.01 0.71 (0.10–5.07)
Type 1 diabetes mellitus
Female 10 0.10 5,406 0.05 1.69 (0.91–3.14)
Male 13 0.11 4,852 0.04 2.26 (1.31–3.89)
All 23 0.10 10,258 0.04 1.97 (1.29–3.02)
Multiple sclerosis
Female 4 0.04 961 0.01 4.86 (1.81–13.00)
Male 0 0 287 0.002 NA
All 4 0.02 1,248 0.01 3.38 (1.26–9.05)
Myasthenia gravis
Female 6 0.06 3,466 0.03 2.12 (0.95–4.73)
Male 2 0.02 2,248 0.02 1.03 (0.26–4.12)
All 8 0.04 5,714 0.02 1.67 (0.83–3.33)
Psoriasis
Female 51 0.64 67,857 0.58 1.29 (0.98–1.70)
Male 74 0.49 45,447 0.38 1.22 (0.97–1.54)
All 125 0.57 113,304 0.48 1.25 (1.04–1.50)
Inflammatory bowel disease
Female 1 0.01 1,026 0.01 1.26 (0.18–8.97)
Male 2 0.02 1,686 0.01 1.18 (0.29–4.72)
All 3 0.01 2,712 0.01 1.21 (0.39–3.76)
Vasculitis
Female 6 0.06 1,837 0.02 4.07 (1.83–9.07)
Male 3 0.03 2,907 0.02 1.22 (0.39–3.79)
All 9 0.04 4,744 0.02 2.29 (1.19–4.40)
* 95% CI5 95% confidence interval; NA5not applicable.
† Adjusted for age, sex, place of residence, quintile of income level, occupation, and family size.
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higher among individuals with an affected first-degree
relative.
Our results have several implications. First, the
study provides quantitative estimates for absolute risks
and RRs, familial transmission, and the proportion of
sporadic cases of SS, which are valuable for clinical
counseling. Second, these data may help in the planning
of future genetic studies to determine candidate suscep-
tibility genes. Third, the co-aggregation of SS and cer-
tain other autoimmune diseases suggests an overlapping
pathogenesis that deserves further elucidation.
Formal evidence for familial aggregation and the
magnitude of any familial or genetic contribution are
rarely reported. Concordance of SS in several twin pairs
has been reported previously (6–9), generally with very
similar phenotypes (e.g., pathologic findings and sero-
logic and clinical presentations). For example, a pair of
monozygotic twins with SS exhibited nearly identical
and clonally restricted anti-Ro/SSA autoantibodies (9).
In addition, several studies in families that include a
member with SS have been reported (10,11,13,14,37,38).
However, previous studies have not included twin con-
cordance rates, tetrachoric correlation coefficients, and
familial transmission.
Our study provides several lines of evidence sup-
porting the importance of familial factors, including both
genes and environment, in susceptibility to SS. First, the
age-specific prevalence of SS was significantly higher in
first-degree relatives of SS patients in all age bands
compared with the general population, and the adjusted
RR associated with a family history was high (12-fold
higher than that in the general population). Second, the
RR and tetrachoric correlation coefficient varied accord-
ing to genetic distance, and sibling RRs are higher than
parental and offspring RRs despite the same genetic dis-
tance, suggesting contributions of both genes and shared
environmental factors to disease susceptibility. Finally,
using a polygenic liability model, we estimated that 54%
of phenotypic variance can be explained by familial
factors.
Under the polygenic liability model, however,
most cases of SS are expected to be sporadic rather than
familial. This phenomenon seems counterintuitive but
appears to be the norm for many common complex dis-
eases (36). For example, a theoretical estimate showed
that the probability of sporadic cases of RA was 78–84%,
depending on the parameters used (36). Real-world
epidemiologic data also support this notion. A prospec-
tive inception cohort study recruited 204 RA patients
with complete family histories, and 162 of the patients
(79.4%) were identified as having sporadic RA (39). A
similar phenomenon exists in SLE (36), despite one study
showing no phenotypic differences between sporadic and
familial cases (40).
Collectively, our results provide useful informa-
tion for counseling patients and their family members.
Full information on familial absolute risks and RRs,
familial transmission, and the probability of sporadic
cases should be provided and fully explained to prevent
misconception and undue distress. Given both a low
absolute risk (,1%) and a high probability of sporadic
cases, decisions based solely on family history to screen
for the disease in asymptomatic family members of the
affected patients do not seem to be justified. Nonethe-
less, further studies should be undertaken to test the
utility of family history as a tool to identify at-risk
individuals.
Recent genome-wide association studies (GWAS)
identified an expanding array of candidate genes that are
associated with an increased risk of SS (41). Recently, 2
GWAS in SS were undertaken (20,21). One of these stud-
ies analyzed 395 patients with SS and 1,975 population
controls of European descent and showed strong associa-
tions with genes within the HLA region (20). Several can-
didate genes outside the regions that were previously
identified, such as STAT4 and IFR5 (18,19), did not
exceed the significance limit. Another study genotyped
597 patients with primary SS and 1,090 healthy controls of
Han Chinese ethnic origin and demonstrated a new sus-
ceptibility locus and also confirmed previously reported
loci (21).
GWAS have also been very successful in identi-
fying candidate genes for other autoimmune disor-
ders, such as RA, SLE, type 1 diabetes mellitus, and
multiple sclerosis. The similarity of the magnitude of
the sibling risk between SS (15-fold) and type 1 diabe-
tes mellitus (15-fold), RA (8-fold), SLE (30-fold), and
multiple sclerosis (20-fold) (42) suggests that it should
be possible to identify specific genetic risk factors for
SS both within and outside the HLA region, in a
relatively small GWAS (;2,000 cases), as was done
for the aforementioned autoimmune diseases (43–45).
Our results therefore may be useful for planning
further GWAS to identify specific susceptibility genes
for SS.
Apart from genetic factors, shared environmen-
tal factors may also contribute to familial clustering of
SS. For example, Epstein-Barr virus (EBV) infection,
with subsequent activation of epithelial cells and the
immune system, has been proposed as a plausible envi-
ronmental factor contributing to the development of
SS (46). EBV most commonly spreads via bodily fluids
(primarily saliva), and family members of infected
patients are potentially at higher risk of infection.
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Therefore, both genetic factors and shared environmental
factors may contribute to the phenotypic variance in SS.
First-degree relatives of patients with SS have an
increased risk of other autoimmune diseases, and the
magnitude of the risk was particularly high for SLE. This
tendency for familial co-aggregation of autoimmune dis-
eases with SS was also suggested previously, but the
magnitude of the risk associated with specific diseases
has not been reported. A multicenter hospital-based
study in Italy comprising 140 patients with SS and 109
in-patient controls without a history of autoimmune dis-
ease showed that patients with SS had a 5-fold risk of
having a first-degree relative with autoimmune diseases
(including 1 with SS) (16). Our results suggest that some
autoimmune diseases share part of the pathogenesis of
SS, but the magnitude of overlapping factors contribut-
ing to disease manifestation is different. Sj€ogren’s syn-
drome appears to share many of these factors with SLE
and RA, which is expected, because SLE and RA often
coexist with SS. A high prevalence of sicca syndrome in
patients with type 1 diabetes mellitus was reported previ-
ously (47), but a link between type 1 diabetes mellitus
and SS was demonstrated only recently (48). The coexis-
tence of multiple sclerosis (49) and vasculitis (50) with
SS has also been reported. Currently, however, there are
no data on familial co-aggregation of these diseases in
families in which a member is affected by SS. Our data
could be of value when counseling families of patients
with SS.
The present study has some limitations. First, the
classification of cases was based purely on the diagnosis
recorded in the registry of patients with catastrophic ill-
nesses or based on records in primary care. The NHIRD is
primarily a health insurance database and lacks full infor-
mation on clinical findings, laboratory testing, and exami-
nations; therefore, formal classification criteria for SS
could not be applied. Nevertheless, issuance of a cata-
strophic illness certificate requires strong medical evidence
for a diagnosis of SS that is agreed upon by an expert
panel, and applications for these certificates are submitted
almost exclusively by rheumatologists. Therefore, any mis-
classification is unlikely to unduly affect our conclusion.
Second, patients with less severe disease may not have
received a certificate and thus will not have been identified
as cases. Third, the estimate for probability of sporadic
cases was based on data derived from first-degree relatives.
In this study, therefore, sporadic cases are limited to
patients with no first-degree relative. Fourth, our model
cannot effectively separate contributions from genetic and
shared environmental factors. Finally, whether these
results apply to different populations and settings outside
of Taiwan requires further study.
In conclusion, this population-wide study con-
firms that in Taiwan, SS clusters within families, and
that both genetic and environmental factors contribute
to susceptibility to the disease. Relatives of patients with
SS tend to have an increased risk of other autoimmune
diseases. These findings may also be useful when coun-
seling families of patients with SS. In addition, these
results may help inform the design of future studies of
familial and genetic risks of SS.
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